DOCSLIB.ORG

Current Treatment of Oral Candidiasis: a Literature Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Current Treatment of Oral Candidiasis: a Literature Review J Clin Exp Dent. 2014;6(5):e576-82. Treatment of oral candidiasis Journal section: Oral Medicine and Pathology doi:10.4317/jced.51798 Publication Types: Review http://dx.doi.org/10.4317/jced.51798 Current treatment of oral candidiasis: A literature review Carla Garcia-Cuesta 1, Maria-Gracia Sarrion-Pérez 2, Jose V. Bagán 3 1 Dentist. Postgraduate in Oral Medicine 2 Associate profesor of Oral Medicine Unit. Department of Stomatology. University of Valencia 3 Chairman of Oral Medicine. Oral Medicine Unit. Department of Stomatology. University of Valencia. Head of the Department of Stomatology and Maxilofacial Surgery. Valencia University General Hospital Correspondence: Avd. / Maestro Rodrigo 13-16 Garcia-Cuesta C, Sarrion-Pérez MG, Bagán JV. Current treatment of oral 46015 Valencia, Spain candidiasis: A literature review. J Clin Exp Dent. 2014;6(5):e576-82. [email protected] http://www.medicinaoral.com/odo/volumenes/v6i5/jcedv6i5p576.pdf Article Number: 51798 http://www.medicinaoral.com/odo/indice.htm © Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488 Received: 19/06/2014 eMail: [email protected] Accepted: 26/07/2014 Indexed in: Pubmed Pubmed Central® (PMC) Scopus DOI® System Abstract Candidiasis or oral candidosis is one of the most common human opportunistic fungal infections of the oral cavity. This pathology has a wide variety of treatment which has been studied until these days. The present study offers a literature review on the treatment of oral candidiasis, with the purpose of establish which treatment is the most suitable in each case. Searching the 24 latest articles about treatment of candidiasis it concluded that the incidence depends on the type of the candidiasis and the virulence of the infection. Although nystatin and amphotericin b were the most drugs used locally, fluconazole oral suspension is proving to be a very effective drug in the treatment of oral candidiasis. Fluconazole was found to be the drug of choice as a systemic treatment of oral candidiasis. Due to its good antifungal properties, its high acceptance of the patient and its efficacy compared with other antifungal drugs. But this drug is not always effective, so we need to evaluate and distinguish others like itraconazole or keto- conazole, in that cases when Candida strains resist to fluconazole. Key words: Candidiasis, treatment, miconazole, fluconazole, nystatin. Introduction Table 1. Predisposing factors. The incidence of fungal infections has been increasing Systemic Local over the last decades, being more prevalent in developed Hormonal disorders Epithelial changes countries (1). An increase incidence of the infections is Physiological disorders Poor oral hygiene associated with some predisposing factors (Table 1) as Endocrine disorders Loss of vertical dimension the use of dentures, xerostomia, prolonged therapy with Immunologic disorders Poor fitting dentures antibiotics, local trauma, malnutrition, endocrine disor- Xerostomia Smoking ders, increased longevity of people, among other states Drug therapy that diminish the quality of defense of the individual (2). Alcohol Oral candidiasis is one of the most common clinical fea- tures of those patients infected with the human immuno- Oropharyngeal candidiasis is caused by the genus Can- deficiency virus [HIV], this manifestation was seen in dida; it is possible to isolate about 150 species. Many up to 90% of individuals infected with HIV (3). of these remain as a commensal micro-organism in hu- e576 J Clin Exp Dent. 2014;6(5):e576-82. Treatment of oral candidiasis mans, which could act as an opportunistic pathogens of- tion; Appropriate use of antifungal drugs, evaluating the ten associated with predisposing factors attributed to the efficacy / toxicity ratio in each case. organism, thereby causing acute or chronic infections When choosing between some treatments it will take (4). The most important of these species is C. albicans, into account the type of Candida, its clinical pathology which is most commonly isolated from the oral cavity and if it is enough with a topical treatment or requires a and is believed to be more virulent in humans, occurring more complex systemic type (8), always evaluating the in approximately 50% of the cases of candidiasis. ratio efficacy and toxicity (9). The different drugs are Clinically there are a number of different types of oral contained in table 3. candidiasis (Table 2). Therefore the choice of therapy is Regular oral and dental hygiene with periodic oral exa- guided by the type of candidiasis. mination will prevent most cases of oral candidiasis, so The diagnosis of oral candidiasis is essentially clinical it is need to make the patient aware of oral hygiene mea- and is based on the recognition of the lesions by the pro- sures. Oral hygiene involves cleaning the teeth, buccal fessional, which can be confirmed by the microscopic cavity, tongue, and dentures. As well as the use of anti- identification of Candida (5). The techniques available Candida rinses such as Chlorhexidine or Hexetidine, so for the isolation of Candida in the oral cavity include that they can penetrate those areas where the brush does direct examination or cytological smear, culture of mi- not. In addition, the need to remove the dentures at night croorganisms and biopsy which is indicated for cases of and wash it consciously, leaving it submerged in a disin- hiperplasic candidiasis because this type could present fectant solution like Chlorhexidine (10). dysplasias (6). This study provides a literature review of the treatment The treatment of oral candidiasis is based on four fun- of oral candidiasis and its objectives are to establish ge- daments (7): making an early and accurate diagnosis of neral guidelines for treatment of oral candidiasis; Assess the infection; Correcting the predisposing factors or un- the drug of choice for local treatment of oral candidiasis; derlying diseases; Evaluating the type of Candida infec- Assess the systemic treatment for oral candidiasis. Table 2. Clinical classification. Acute Chronic Other lesions Pseudomembranous Pseudomembranous Angular cheilitis Erythematous Erythematous Denture-associated erythematous Hyperplastic Median rhomboid glossitis Table 3. Antifungal agents. Vademecum. DRUG FORMULATION DOSE ADVERSE EFFECT Anfotericin b 50mg for infusion 100-200mg/6h Renal, cardiovascular, spinal and neurological Nystatin Suspension 60ml 4-6ml / 6h Well tolerated. Ointment 30g 2 to 4 applications / day Tablets 2 every 8h Uncommon Nausea, vomiting, gastrointestinal effects Clotrimazole Gel 1% 3 times / day Occasionally Skin irritation, burning sensation Tablets 10mg 5 times / day Miconazole Gel 100mg /6h Uncommon Burning, irritation, nausea, diarrhea, Ketoconazole Gel 2% 3 times/ day Nausea, vomiting Tablets 200mg 1-2/day Abdominal pain. Suspension 30 or 10cc Fluconazole Tablets 50 - 100mg/day Nausea, vomiting, diarrhea, abdominal pain. Suspension 10mg/ml Itraconazole Capsule 100-200mg/day Nausea, vomiting, diarrhea, abdominal pain. e577 J Clin Exp Dent. 2014;6(5):e576-82. Treatment of oral candidiasis Material and Methods As first choice for local treatment has been for years the A Medline-PubMed search was made using the fo- nystatin at doses of 100 000 IU/ml [5ml 4 times daily] llowing key words: “ oral candidiasis” OR “oral candi- and amphotericin b at 50mg [5ml 3 times per day]. This dosis” AND amphotericin, “oral candidiasis” OR “oral choice is because they are poorly absorbed by the in- candidosis” AND nystatine, “oral candidiasis” OR “oral testinal tract and therefore most of the antifungal is ex- candidosis” AND miconazole, “oral candidiasis” OR creted without undergoing any change, thereby reducing “oral candidosis” AND ketoconazole, “oral candidiasis” hepatotoxicity (14). However, the unpleasant taste and OR “oral candidosis” AND clotrimazole, “oral candidia- prolonged pattern compromise treatment compliance by sis” OR “oral candidosis” AND fluconazole, “oral can- the patient (14-16). didiasis” OR “oral candidosis” AND itraconazole, “oral Throughout the years it has been studying the effective- candidiasis” OR “oral candidosis” AND treatment, “oral ness of other drugs like fluconazole oral solution. Many candidiasis” OR “oral candidosis” AND “antifungal authors have focused on evaluating the efficacy and therapy”.The key words were validated by the MeSH safety of fluconazole oral solution for the treatment of [Medical Subject Headings] dictionary, with use of the oropharyngeal candidiasis, especially pseudomembra- boolean operator “AND” to relate them. nous type, giving good results, although many studies The following limits for inclusion of the studies were esta- are still needed (14-18). blished: articles published from 2000, publications in En- In a recent study conducted in 19 patients with pseudo- glish and Spanish and publications of studies in humans. membranous candidiasis show that fluconazole suspen- All systematic reviews, clinical trials, meta-analysis and sion in distilled water [2mg/ml] reaches a 95% cure. comparative studies were considered in this review. The guideline was to rinse with 5ml of the drug solution A total of 109 articles were identified, of which 30 were for 1 minute and then spit it out and repeat this action selected after reading the abstracts. Following analysis 3 times a day for 1 week. Another study which inclu- of the 30 articles, we finally included a total of 24, since ded 36 children with pseudomembranous candidiasis those publications that did not fit the aims of the present showed
Load more

Recommended publications
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Oral Candidosis: Aetiology, Clinical Manifestations, Diagnosis and Management Birsay Gümrü Tarçın
    MÜSBED 2011;1(2):140-148 Derleme / Review Oral Candidosis: Aetiology, Clinical Manifestations, Diagnosis and Management Birsay Gümrü Tarçın Marmara University Faculty of Dentistry, Department of Oral Diagnosis and Radiology, Istanbul-Turkey Ya zış ma Ad re si / Add ress rep rint re qu ests to: Birsay Gümrü Tarçın Marmara University Faculty of Dentistry, Department of Oral Diagnosis and Radiology, Büyükçiftlik Sok. No: 6 34365 Nişantaşı, Şişli, İstanbul-Turkey Telefon / Phone: +90-212-231-9120 Faks / Fax: +90-212-246-5247 Elekt ro nik pos ta ad re si / E-ma il add ress: [email protected] Ka bul ta ri hi / Da te of ac cep tan ce: 22 Ağustos 2011 / August 22, 2011 ÖZET ABS TRACT Oral kandidozis: Etiyoloji, klinik özellikler, tanı Oral candidosis: aetiology, clinical ve tedavi manifestations, diagnosis and management Oral kandidozis dişhekimliği pratiğinde en sık karşılaşılan fungal Oral candidosis is the most common fungal infection encountered enfeksiyondur. Birçok farklı klinik görünümde ortaya çıkabildi- in dental practice. Clinical diagnosis and management of oral ğinden, klinik tanı ve tedavisi genellikle zordur. Hastalık sıklıkla candidosis is usually complicated, because it is encountered in a sistemik rahatsızlığı olan spesifik hasta gruplarında ortaya çık- wide variety of clinical presentations. The disease often manifests maktadır. Bu nedenle, oral kandidozis tedavisi öncelikle predis- in specific patient groups that are systemically compromised. pozisyon yaratan durumların kapsamlı tetkikini içermelidir. Bu Therefore, the management should always cover a thorough derlemede sık karşılaşılan oral kandidal lezyonların etiyolojisi, investigation of underlying predisposing conditions. This klinik görünümü, tanı ve tedavi stratejileri kapsamlı bir şekilde review provides a comprehensive overview of the aetiology, gözden geçirilmektedir.
    [Show full text]
  • Adverse Effects of Medications on Oral Health
    Adverse Effects of Medications on Oral Health Dr. James Krebs, BS Pharm, MS, PharmD Director of Experiential Education College of Pharmacy, University of New England Presented by: Rachel Foster PharmD Candidate, Class of 2014 University of New England October 2013 Objectives • Describe the pathophysiology of various medication-related oral reactions • Recognize the signs and symptoms associated with medication-related oral reactions • Identify the populations associated with various offending agents • Compare the treatment options for medication-related oral reactions Medication-related Oral Reactions • Stomatitis • Oral Candidiasis • Burning mouth • Gingival hyperplasia syndrome • Alterations in • Glossitis salivation • Erythema • Alterations in taste Multiforme • Halitosis • Oral pigmentation • Angioedema • Tooth discoloration • Black hairy tongue Medication-related Stomatitis • Clinical presentation – Aphthous-like ulcers, mucositis, fixed-drug eruption, lichen planus1,2 – Open sores in the mouth • Tongue, gum line, buccal membrane – Patient complaint of soreness or burning http://www.virtualmedicalcentre.com/diseases/oral-mucositis-om/92 0 http://www.virtualmedicalcentre.com/diseases/oral-mucositis-om/920 Medication-related Stomatitis • Offending agents1,2 Medication Indication Patient Population Aspirin •Heart health • >18 years old •Pain reliever • Cardiac patients NSAIDs (i.e. Ibuprofen, •Headache General population naproxen) •Pain reliever •Fever reducer Chemotherapy (i.e. •Breast cancer •Oncology patients methotrexate, 5FU, •Colon
    [Show full text]
  • Oral Manifestations of Pemphigus Vulgaris
    Journal of Clinical & Experimental Dermatology Research - Open Access Research Article OPEN ACCESS Freely available online doi:10.4172/2155-9554.1000112 Oral Manifestations of Pemphigus Vulgaris: Clinical Presentation, Differential Diagnosis and Management Antonio Bascones-Martinez1*, Marta Munoz-Corcuera2, Cristina Bascones-Ilundain1 and German Esparza-Gómez1 1DDS, PhD, Medicine and Bucofacial Surgery Department, Dental School, Complutense University of Madrid, Spain 2DDS, PhD Student, Medicine and Bucofacial Surgery Department, Dental School, Complutense University of Madrid, Spain Abstract Pemphigus vulgaris is a chronic autoimmune mucocutaneous disease characterized by the formation of intraepithelial blisters. It results from an autoimmune process in which antibodies are produced against desmoglein 1 and desmoglein 3, normal components of the cell membrane of keratinocytes. The first manifestations of pemphigus vulgaris appear in the oral mucosa in the majority of patients, followed at a later date by cutaneous lesions. The diagnosis is based on clinical findings and laboratory analyses, and it is usually treated by the combined administration of corticosteroids and immunosuppressants. Detection of the oral lesions can result in an earlier diagnosis. We review the oral manifestations of pemphigus vulgaris as well as the differential diagnosis, treatment, and prognosis of oral lesions in this uncommon disease. Keywords: Pemphigus; Oral mucosa; Autoimmune bullous disease and have a molecular weight of 130 and 160 KDa, respectively [1,7,9,13]. The binding of antibodies to desmoglein at mucosal or Introduction cutaneous level gives rise to the loss of cell adhesion, with separation of epithelial layers (acantholysis) and the consequent appearance of Pemphigus vulgaris (PV) is the most frequently observed blisters on skin or mucosae [1,3].
    [Show full text]
  • National OTC Medicines List
    National OTC Medicines List ‐ DraŌ 01 DRAFT National OTC Medicines List Draft 01 Ministry of Public Health of Lebanon This list was prepared under the guidance of His Excellency Minister Waêl Abou Faour andDRAFT the supervision of the Director General Dr. Walid Ammar. Editors Rita KARAM, Pharm D. PhD. Myriam WATFA, Pharm D Ghassan HAMADEH, MD.CPE FOREWORD According to the French National Agency for Medicines and Health Products Safety (ANSM), Over-the-counter (OTC) drugs are medicines that are accessible to patients in pharmacies, based on criteria set to safeguard patients’ safety. Due to their therapeutic class, these medicines could be dispensed without physician’s intervention for diagnostic, treatment initiation or maintenance purposes. Moreover, their dosage, treatment period and Package Insert Leaflet should be suitable for OTC classification. The packaging size should be in accordance with the dosage and treatment period. According to ArticleDRAFT 43 of the Law No.367 issued in 1994 related to the pharmacy practice, and the amendment of Articles 46 and 47 by Law No.91 issued in 2010, pharmacists do not have the right to dispense any medicine that is not requested by a unified prescription, unless the medicine is mentioned in a list which is established by pharmacists and physicians’ syndicates. In this regard, the Ministry of Public Health (MoPH) developed the National OTC Medicines List, and presentedit in a scientific, objective, reliable, and accessible listing. The OTC List was developed by a team of pharmacists and physicians from the Ministry of Public Health (MoPH). In order to ensure a safe and effective self- medicationat the pharmacy level, several pharmaceutical categories (e.g.
    [Show full text]
  • On the Tip of the Tongue
    KNOWLEDGE TO PRACTICE DES CONNAISSANCES ÀLA PRATIQUE Diagnostic Challenge On the tip of the tongue . Rachel Orchard, MD*; Sheena Belisle, MD†; Rodrick Lim, MD†‡ Keywords: pediatric, rash, tongue, vesicle right-sided wheeze. Cardiovascular, abdominal, and neurological (including cranial nerve) examinations were unremarkable. CASE HISTORY What is the most likely diagnosis? A 14-year-old male presented to the pediatric emer- a) Drug eruption gency department (ED) with a chief complaint of b) Varicella zoster virus (VZV) changes to his tongue. He described a 3-day history of a c) Oral candidiasis gradually worsening sore, swollen tongue associated with a white plaque. This was accompanied by a 3-day d) Epstein-Barr virus history of a gradually worsening left-sided facial rash e) Oral lichen planus that had an intermittent mild tingling sensation. He also had a 1-week history of a productive cough with yellow mucus and generalized malaise. He had been seen at a walk-in clinic 2 days prior to presentation and was prescribed amoxicillin for presumed pneumo- nia, which he began the same day. He denied any history of fevers, facial weakness, neck stiffness, or eye symptoms. He was an otherwise well child, with up-to-date immunizations and a past medical history of chickenpox and recurrent furuncles as a younger child. On examination, he appeared well with the following vital signs: blood pressure 122/64 mm Hg, heart rate 73 beats per minute, respiratory rate 18 breaths per minute, temperature 36.8°C, and oxygen saturation of 99% on room air. Examination of his tongue revealed a symmetric white plaque along with ulcerative lesions on the left tongue and buccal mucosa (Figure 1).
    [Show full text]
  • First-Line Treatment of Oral Candidiasis in Adults
    No. 628017 First-line Treatment of Oral Candidiasis in Adults Developed in collaboration with an advisory committee consisting of Québec clinicians and experts. Validated by the Comité d’excellence clinique en usage optimal du médicament, des protocoles médicaux nationaux et ordonnances of the Institut national d’excellence en santé et en services sociaux (INESSS). CLINICAL SITUATION OR TARGET POPULATION Person aged 18 years and older with one or several of the following clinical signs and symptoms: ► Sensation of burning, discomfort or general pain in the mouth or at the corners of the mouth, which worsens when eating food1 ► White patches that can be scraped away more or less easily; redness on the mucous membranes of the mouth. ► Cracked skin or slight bleeding at the corners of the mouth, which may extend to marionette lines. ► Total or partial loss of papillae on the surface of the tongue. CONTRAINDICATIONS TO THE APPLICATION OF THIS PROTOCOL ► Contraindication or history of allergic reaction to the recommended medication. ► Known case of refractory oral candidiasis. ► Oral candidiasis recurrence within one month of initial treatment. ► White patches that appear unilaterally on the tongue or cannot be scraped away. ► Bite or sore marks on the inside of the cheeks or on the tongue. ► Gum or submaxillary swelling. ► Surgery, injury, trauma, cut, burns in the mouth, or oral health problems (e.g. viral, bacterial or fungal infections) within the past two (2) weeks. ► Oral pain, localized or unilateral. ► Difficulty in swallowing, pain or burning sensation in the sternum or chest (suggesting esophageal candidiasis). ► Constant burning sensation that lessens when eating food (suggesting stomatopyrosis).
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • New Mechanism of Oral Immunity to Mucosal Candidiasis in Hyper-Ige Syndrome
    ARTICLES nature publishing group New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome H R C o n t i 1 , 4 , O B a k e r 1 , A F F r e e m a n 2 , W S J a n g 1 , S M H o l l a n d 2 , R A L i 1 , M E d g e r t o n 1 a n d S L G a f f e n 1 , 3 Oropharyngeal candidiasis (OPC, thrush) is an opportunistic infection caused by the commensal fungus Candida albicans . An understanding of immunity to Candida has recently begun to unfold with the identification of fungal pattern- recognition receptors such as C-type lectin receptors, which trigger protective T-helper (Th)17 responses in the mucosa. Hyper-IgE syndrome (HIES / Job ’ s syndrome) is a rare congenital immunodeficiency characterized by dominant-negative mutations in signal transducer and activator of transcription 3, which is downstream of the Th17-inductive cytokines interleukin (IL)-6 and IL-23, and hence patients with HIES exhibit dramatic Th17 deficits. HIES patients develop oral and mucocutaneous candidiasis, supporting a protective role for Th17 cells in immunity to OPC. However, the Th17- dependent mechanisms of antifungal immunity in OPC are still poorly defined. An often unappreciated aspect of oral immunity is saliva, which is rich in antimicrobial proteins (AMPs) and exerts direct antifungal activity. In this study, we show that HIES patients show significant impairment in salivary AMPs, including -defensin 2 and Histatins. This tightly correlates with reduced candidacidal activity of saliva and concomitantly elevated colonization with Candida .
    [Show full text]
  • Oral Candidiasis (Oral Thrush) Lesson
    Single Point Oral candidiasis (Oral Thrush) Lesson Oral candidiasis, also known as oral thrush that occurs in the mouth. Oral candidiasis is a mycosis (yeast/fungal infection) of Candida species on the mucous membranes of the mouth. Thrush (oropharyngeal candidiasis) is a medical condition in which a yeast-shaped fungus called Candida Albicans overgrows in the mouth and throat. For people with lowered immunity, such as from cancer treatment or HIV/AIDS, thrush can be more serious. Untreated oral thrush can lead to more-serious systemic candida infections. If you have a weakened immune system, thrush may spread to your oesophagus or other parts of your body. If Oral Thrush is not treated it can spread Main anti-fungal agents used for Oral Thrush Symptoms to other parts of the body. • Creamy white bumps on the • Nystatin Suspension tongue, inner cheeks, gums • Miconazole oral Gel or tonsils. • Fluconazole Oral • Slight bleeding when the Further guidance (NICE): https://cks.nice.org.uk/candida- bumps are scraped. oral#!prescribinginfo ) • Pain at the site of the bumps. • dry, cracked skin at the corners of the mouth. Who is susceptible? • Difficulty swallowing. • Oral thrush is not considered • New born Babies contagious. • Diabetics • Drug users Denture stomatitis (chronic • Immune compromised erythematous candidiasis or chronic • Smokers atrophic oral candidiasis) presents with redness, and rarely soreness, in • Those with poor diets the denture-bearing area. It affects • Those with poor oral about 50–70% of denture wearers. hygiene. Please contact Karen Jones or the infection control team on 01744 457314/01744 457312 if you require any additional advice/support.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,265,775 B2 Lyons Et Al
    US009265775B2 (12) United States Patent (10) Patent No.: US 9,265,775 B2 Lyons et al. (45) Date of Patent: *Feb. 23, 2016 (54) PHARMACEUTICAL COMPOSITIONS 4,281,654 A 8, 1981 Shell et al. 4,285,987 A 8/1981 Ayer et al. 4,303,637 A 12/1981 Shell et al. (71) Applicant: Allergan, Inc., Irvine, CA (US) 4,304.765 A 12/1981 Shell et al. 4,327,725 A 5, 1982 Cortese (72) Inventors: Robert T. Lyons, Laguna Hills, CA 4,383,992 A 5/1983 Lipari (US); James N. Chang, Newport Beach, 4,396,625 A 8/1983 Yamamori et al. CA (US); John T. Trogden, Villa Park, 4.425,346 A 1/1984 Horlington et al. 4,474,451 A 10, 1984 Mizokami CA (US); Scott Whitcup, Laguna Hills, 4,478,818 A 10, 1984 Shell et al. CA (US) 4,494,274 A 1/1985 Thurlow 4,521,210 A 6/1985 Wong (73) Assignee: Allergan, Inc., Irvine, CA (US) 4,599,353 A 7, 1986 Bito 4,649,151 A 3/1987 Dougherty et al. (*) Notice: Subject to any disclaimer, the term of this 4,656,186 A 4, 1987 Bommer et al. 4,668,506 A 5, 1987 Bawa patent is extended or adjusted under 35 4.675,338 A 6, 1987 Bommer et al. U.S.C. 154(b) by 0 days. 4,693,885 A 9, 1987 Bommer et al. 4,712,500 A 12/1987 Montandon This patent is Subject to a terminal dis 4,713,446 A 12/1987 DeVore et al.
    [Show full text]